ES019 targets two checkpoint inhibitors – PD-L1 and SIRP-alpha – that work in different ways to boost immune responses against cancers. Targeting SIRP-alpha primes macrophages to attack and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback